Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Karuna Therapeutics Inc (Karuna Therapeutics), a subsidiary of Bristol-Myers Squibb Co, is a biopharmaceutical company that focuses on developing medicines for neurological and psychiatric conditions. It is investigating its lead product candidate KarXT, an oral modulator of muscarinic receptors for the treatment of schizophrenia, negative and cognitive symptoms of schizophrenia and Alzheimer’s disease. The company's other pipeline products include KAR-2618, KAR-401, KAR-501, KAR-201 and KAR-301. Its lead product candidate combines xanomeline, a novel muscarinic agonist that stimulates muscarinic receptors in the central nervous system. Karuna Therapeutics is headquartered in Boston, Massachusetts, the US.
Karuna Therapeutics Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
KarXT (xanomeline-Trospium): Schizophrenia, Alzheimer’s Disease |
KAR-2618 (TRPC4/5 Inhibitor): Mood and Anxiety Disorders |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Contracts/Agreements | In December, the company entered an agreement to be acquired by Bristol Myers Squibb for US$14 billion. |
2023 | Regulatory Approval | In November, the company received the US Food and Drug Administration approval for its New Drug Application for KarXT (xanomeline-trospium) for the treatment of schizophrenia in adults. |
2023 | Others | In September, the company announced the submission of a New Drug Application to the US Food and Drug Administration for KarXT (xanomeline-trospium) to treat schizophrenia. |
Competitor Comparison
Key Parameters | Karuna Therapeutics Inc | Pfizer Inc | Novartis AG | Eli Lilly and Co | Boehringer Ingelheim International GmbH |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | Switzerland | United States of America | Germany |
City | Boston | New York | Basel | Indianapolis | Ingelheim am Rhein |
State/Province | Massachusetts | New York | - | Indiana | Rheinland-Pfalz |
No. of Employees | 339 | 88,000 | 76,057 | 43,000 | 53,000 |
Entity Type | Private | Public | Public | Public | Private |
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Sandra Ramos-Alves | President; Treasurer | Senior Management | 2024 | - |
Scott Matarese | Vice President | Senior Management | 2024 | - |
Kimberly M. Jablonski | Vice President; Secretary | Senior Management | 2024 | - |
Sophia Park | Vice President | Senior Management | 2024 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer